Väljaminev kiriAvalik
Euroopa farmakopöa töökava asjus
Ravimiamet · 5. märts 2025
- Viit
- REP-1/1197-2
- Registreeritud
- 5. märts 2025
- Dokumendi liik
- Väljaminev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2025
- Vastutaja
- Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)
Sisu (failidest)
Addition to the work programme of Group 17 – Sodium Patent Blue and
Sodium Patent Blue solution for injection
page 1 / 4
Q1-4 (3949)
NPA: (51425)
Type: (!/list-dropdown)
A10 - Estonia (EE)
Please inform if you are in favour of the addition of the monograph on Sodium Patent Blue to
the work programme:
(51426)
Type: (L/list-radio)
Not interested
A2
If opposed to this addition to the work programme, please state why. (51427)
Type: (T/text-long)
-
page 2 / 4
Please inform if you are in favour of the addition of the monograph on Sodium Patent Blue
solution for injection to the work programme:
(51429)
Type: (L/list-radio)
Not interested
A2
If opposed to this addition to the work programme, please state why. (51428)
Type: (T/text-long)
-
Could you please provide the contact details (e.g. e-mail address, if available) of approved
manufacturers for Sodium Patent Blue and Sodium Patent Blue solution for injection in your
country? (51431)
Type: (T/text-long)
n.a
Remarks: (51430)
Type: (T/text-long)
-
page 3 / 4
page 4 / 4